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RESULTS: In spite of the same quality of life score at the ﬁ rst session of chemotherapy 
(74.5 out of 100), after ﬁ nishing the chemotherapy cycle, patients in TAC arm had 
the lower score of QOL (64 in TAC vs. 68 in FAC) and higher range of toxicity and 
their medical costs were higher as well (the average costs in TAC was 391,176,968.2 
Rials vs. 2,427,775.2 in FAC). ICER was negative that showed the dominant result 
for FAC comparing with TAC. CONCLUSIONS: It seems that because of the short 
horizon of the study, TAC regimen had the worse impact on the patient’s quality of 
life during the chemotherapy cycle because of more side effects than FAC. It is believed 
that there is need for other studies with longer time horizons and speciﬁ c attention to 
the effects of these treatments on survival and quality of life.
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OBJECTIVES: Breast cancer is known to be one of the leading causes of death among 
the female population. Preventive measures may provide an economic and outcome 
advantage by reducing treatment costs and increasing survival. The objective of this 
study was to evaluate the cost-effectiveness of a breast cancer vaccine versus current 
standard treatments. METHODS: TreeAge software was used to calculate the cost-
effectiveness. a decision tree was constructed for different probabilities of success and 
failure for the vaccine versus standard treatment. Costs and outcomes (life-years saved) 
ranges were obtained from published clinical trials. The vaccine effectiveness was 
projected from animal studies, with human clinical trials expected within a year. The 
range of effectiveness of the vaccine was considered between 30% and 90% with a 
baseline at 80%. The costs included for standard treatments ranged from $20,000 to 
$45,000 and the cost of the vaccine was assumed at $450 for three doses; therefore, 
the cost for vaccine ranged from $300 to $2000 depending on the number of doses. 
The incremental cost-effectiveness ratios were calculated from the range of costs and 
outcomes. Sensitivity analyses were performed to determine the robustness of the 
ﬁ ndings. RESULTS: Vaccination was found to be a potentially cost-effectiveness 
option with an ICER of 2384.146 relative to standard treatment. The incremental 
effectiveness was 8.2 life-years saved. The highest cost-effectiveness of the vaccine was 
at 90% success and a cost of not more than $1000 per individual. Sensitivity analyses 
indicated that the vaccine remained cost-effective over the range of model parameters. 
CONCLUSIONS: The breast cancer vaccine was projected to be the most cost-
effective treatment option in this analysis. It is expected that better screening for breast 
cancer vaccine patient candidates will be available in the future.
PCN90
COMPARATIVE RETROSPECTIVE NON-RANDOMIZED 
PHARMACOECONOMIC TRIAL OF EFFICIENCY AND SAFETY OF USE 
OF PACLITAXELS (PACLITAXEL-LENS OR TAXOL) IN A MONOMODE 
FOR 2ND LINE OF TREATMENT OF METASTATIC BREAST CANCER 
PATIENTS
Pavlysh A1, Kolbin A2, Livshits R2, Koroleva O2, Manikhas A1, Tkachenko E1, 
Atrashevskaya N1, Demicheva N1
1Saint Petersburg City Clinical Oncology Dispensary, Saint Petersburg, Russi; 2Saint 
Petersburg State University, Saint Petersburg, Russia
OBJECTIVES: For the ﬁ rst time in a modern Russian economic conditions, it has been 
made pharmacoeconomics trial (PE) uses Russian generic of paclitaxel (Paclitaxel-Lens 
[PL]) in comparison with original drug (Taxol (T)) at chemotherapy (ChT) in a 
monomode for 2nd line of metastatic breast cancer (MBC) in real clinical practice. 
METHODS: It has been provided retrospective comparative nonrandomized clinical 
trial which have been included 70 patients for 35 patients of each group (PL or T) 
after analysis of 148 case records. RESULTS: At the analysis of effectively treatment 
MBC in group of the patients who have received T, the partial remission (PR, 28.5% 
against 10%) statistically signiﬁ cantly has been more often reached. At the analysis 
of safety, it has been shown that in group of the patients who have received PL, 
statistically signiﬁ cantly has been more often ﬁ xed hepatotoxicity (23.3% against 
3.8%) and an anemia (19.2% against 3.5%). In group of the patients who have 
received T, statistically signiﬁ cantly has been more often ﬁ xed arthralgia/ myalgia 
(29.8% against 0%). Total direct costs (DC) in group of patients with T also there 
were above, than in group of PL, namely $10,727 and $9765 accordingly. Calculation 
of efﬁ ciency of expenses has shown that treatment of MBC by T more expensive and 
more effective, than treatment by PL. CONCLUSIONS: Thus, as a result of research, 
it has been established that: 1) Applying of T was more (from 7% to 11%) expensive, 
than PL, but gave the PR is much more often; 2) The alternative scenario and the 
sensitivity analysis shown to choose conditions when application of compared drugs 
will be economically more expedient; and 3) Thus, it is necessary to take into consid-
eration, what application of PL was more often accompanied by hepatotoxicity and 
anemia, like arthralgia/ myalgia after using of T.
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OBJECTIVES: To determine and compare the cost-effectiveness of Bev + Pac + Car 
versus Pem + Cis regimens in the treatment of patients with adenocarcinoma non-
squamous NSCLC from a Polish Public Payer’s perspective. METHODS: Efﬁ cacy and 
safety of 15 mg of bevacizumab + 200 mg/m2 of paclitaxel + 6 mg/mL/min of carbo-
platin versus 500 mg/m2 of pemetrexed and 75 mg/m2 of cisplatin was assessed based 
on a systematic review performed for both therapies according to evidence-based 
medicine principles. A cost-effectiveness analysis was performed with a lifetime (5 
years) horizon and the National Health Fund perspective. a three state (progression-
free, progression, death) Markov model was developed. Costs of 1st and 2nd line 
therapy, administration and monitoring, adverse events treatment, and palliative care 
were included. Sensitivity analyses testing the inﬂ uence of length of time horizon, 
probability of progression, utilities, discounting rates, cisplatin dose, and the length 
and costs of 2nd line therapy were performed. RESULTS: Bev + Pac + Car results in 
0.21 life-years gained per patient when compared to Pem + Cis in the treatment of 
patients with adenocarcinoma non-squamous NSCLC. The additional cost per patient 
was 18,840 pln (1 EURO = 4.1PLN) over patient’s lifetime when Bev + Pac + Car 
was used instead of Pem + Cis regimen. The incremental cost-effectiveness ratio (ICER) 
was at an acceptable 91,216 pln. The sensitivity analyses demonstrated that the dura-
tion of 2nd line treatment (assumption of 2nd line treatment continuation for more 
than six cycles) considerably inﬂ uenced the ICER (1,198 pln). Other sensitivity analy-
ses conﬁ rmed the base-case results, proving conclusions’ robustness. CONCLUSIONS: 
Based on this modeling analysis, 1st line Bev + Pac + Car therapy is a clinically superior 
and cost-effective treatment for patients with adenocarcinoma non-squamous NSCLC 
when compared to chemotherapies such as Pem + Cis.
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The problem of original drugs substitution on generics presents in the Russian clinical 
practice due to rational expenditures allocation. Pharmaceutical bioequivalence of 
generic should be conﬁ rmed by therapeutic one. Only after such kind of conﬁ rmation, 
the mentioned substitution could be made in different segments of doctors’ practice 
especially in anticancer chemotherapy. OBJECTIVES: To evaluate the clinical-eco-
nomic interchangeability of the original oxaliplatin Eloxatine (EL) and local generic 
Exorum (EX) in the chemotherapy of mCCR. METHODS: The retrospective clinical-
economic analysis of FOLFOX scheme for chemotherapy of mCCR with EL and EX 
in the real practice has been performed. Fifty case histories (23 with using of EL, 
27—EX, was used nomogram of Altman’s) were studied. The calculation of direct 
cost and cost-effectiveness ratio (CER) based on “partial regress + stabilization” 
parameter no less than 80% has been performed. RESULTS: For achievement of equal 
efﬁ cacy EL had less number of chemotherapy cycles and total dosage compared with 
EX (5,0 and 7,3; 670 mg and 900 mg, respectively). Adverse effects were more fre-
quent in EX versus EL (59 and 38, respectively) and caused additional costs and 
prolonged hospitalization (9 days/patient compared to EL group). The utilitarian EX 
program cost per patient was less compared to EL by 7,7%. In the same time, CER 
calculated with total costs due to side effects treatment was practically equal (differ-
ence is 1,6% only). Cost prognosis for equal efﬁ cacy results with EL using is less by 
28,6% versus EX. The alternative scenario has conﬁ rmed the cinical-economic added 
value of EL. CONCLUSIONS: The change of original EL for generic EX in FOLFOX 
scheme for mCCR has no economic advantages. EL substitution leads to increased 
number of chemotherapy cycles, higher dose of oxaliplatin, higher rate of adverse 
effects, and higher costs.
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BACKGROUND: Colorectal cancer is the third leading cancer worldwide (INCA) 
with nearly 1.2 million cases and about 630,000 deaths expected in 2007 (ACS 2007). 
In Brazil, it is estimated 28,110 new cases in 2010 (INCA 2010). For patients with 
stage III colon cancer, the beneﬁ ts from ﬂ uorouracil (5-FU)-based adjuvant chemo-
